Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q01973
UPID:
ROR1_HUMAN
Alternative names:
Neurotrophic tyrosine kinase, receptor-related 1
Alternative UPACC:
Q01973; Q5VVX6; Q66K77; Q92776
Background:
Inactive tyrosine-protein kinase transmembrane receptor ROR1, alternatively known as Neurotrophic tyrosine kinase, receptor-related 1, exhibits low kinase activity, suggesting its non-kinase role in vivo. It serves as a receptor for WNT5A, activating the NFkB signaling pathway, which may inhibit WNT3A-mediated signaling. Crucially, it supports the innervation of auditory hair cells by spiral ganglion neurons.
Therapeutic significance:
ROR1's involvement in autosomal recessive deafness, 108, highlights its potential as a therapeutic target. Understanding the role of ROR1 could open doors to potential therapeutic strategies for sensorineural hearing loss.